Latest Insider Transactions at Deciphera Pharmaceuticals, Inc. (DCPH)
This section provides a real-time view of insider transactions for Deciphera Pharmaceuticals, Inc. (DCPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Deciphera Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Deciphera Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 18
2022
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+29.41%
|
-
|
|
Dec 15
2021
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,300
+18.67%
|
-
|
|
Dec 15
2021
|
Daniel Lee Flynn Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,100
+27.87%
|
-
|
|
Dec 15
2021
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,100
+16.23%
|
-
|
|
Dec 15
2021
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,300
+24.6%
|
-
|
|
Dec 15
2021
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,100
+27.88%
|
-
|
|
Oct 04
2021
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,659
-5.46%
|
$87,747
$33.17 P/Share
|
|
May 03
2021
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
8,000
-98.13%
|
$368,000
$46.41 P/Share
|
|
May 03
2021
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+45.69%
|
$16,000
$2.92 P/Share
|
|
Apr 20
2021
|
James Arthur Bristol |
SELL
Open market or private sale
|
Direct |
1,700
-100.0%
|
$76,500
$45.6 P/Share
|
|
Apr 20
2021
|
James Arthur Bristol |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+50.0%
|
$5,100
$3.95 P/Share
|
|
Apr 19
2021
|
James Arthur Bristol |
SELL
Open market or private sale
|
Direct |
5,300
-87.74%
|
$243,800
$46.4 P/Share
|
|
Apr 19
2021
|
James Arthur Bristol |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+50.0%
|
$15,900
$3.95 P/Share
|
|
Apr 12
2021
|
James Arthur Bristol |
SELL
Open market or private sale
|
Direct |
14,700
-82.26%
|
$632,100
$43.9 P/Share
|
|
Apr 12
2021
|
James Arthur Bristol |
BUY
Exercise of conversion of derivative security
|
Direct |
14,700
+50.0%
|
$44,100
$3.95 P/Share
|
|
Apr 01
2021
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
8,000
-70.3%
|
$360,000
$45.74 P/Share
|
|
Apr 01
2021
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+50.0%
|
$8,000
$1.89 P/Share
|
|
Mar 18
2021
|
Steven L. Hoerter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,150
-3.64%
|
$132,300
$42.79 P/Share
|
|
Mar 01
2021
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
8,000
-93.1%
|
$352,000
$44.31 P/Share
|
|
Mar 01
2021
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+50.0%
|
$8,000
$1.89 P/Share
|
|
Feb 16
2021
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,100
+18.66%
|
-
|
|
Feb 16
2021
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
132
-0.35%
|
$6,336
$48.87 P/Share
|
|
Feb 16
2021
|
Daniel Lee Flynn Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,100
+38.63%
|
-
|
|
Feb 16
2021
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
508
-7.22%
|
$24,384
$48.87 P/Share
|
|
Feb 16
2021
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,100
+38.65%
|
-
|
|
Feb 16
2021
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
524
-7.44%
|
$25,152
$48.87 P/Share
|
|
Feb 01
2021
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
8,000
-72.83%
|
$360,000
$45.31 P/Share
|
|
Feb 01
2021
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+50.0%
|
$8,000
$1.89 P/Share
|
|
Jan 21
2021
|
Steven L. Hoerter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,078
+2.4%
|
$26,950
$25.4 P/Share
|
|
Jan 15
2021
|
James Arthur Bristol |
SELL
Open market or private sale
|
Direct |
7,000
-95.71%
|
$350,000
$50.66 P/Share
|
|
Jan 15
2021
|
James Arthur Bristol |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$21,000
$3.95 P/Share
|
|
Jan 04
2021
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
19,000
-71.92%
|
$1,064,000
$56.63 P/Share
|
|
Jan 04
2021
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+50.0%
|
$19,000
$1.89 P/Share
|
|
Dec 09
2020
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
207
+0.55%
|
$7,038
$34.43 P/Share
|
|
Dec 01
2020
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
19,000
-76.98%
|
$1,159,000
$61.55 P/Share
|
|
Dec 01
2020
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+50.0%
|
$19,000
$1.89 P/Share
|
|
Nov 16
2020
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,697
+6.76%
|
$91,698
$34.43 P/Share
|
|
Nov 04
2020
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
15,000
-90.56%
|
$975,000
$65.01 P/Share
|
|
Nov 04
2020
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Nov 02
2020
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
23,315
-69.73%
|
$1,328,955
$57.77 P/Share
|
|
Nov 02
2020
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,315
+50.0%
|
$23,315
$1.89 P/Share
|
|
Oct 09
2020
|
James Arthur Bristol |
SELL
Open market or private sale
|
Direct |
23,541
-92.5%
|
$1,271,214
$54.44 P/Share
|
|
Oct 09
2020
|
James Arthur Bristol |
BUY
Exercise of conversion of derivative security
|
Direct |
23,541
+50.0%
|
$23,541
$1.89 P/Share
|
|
Oct 02
2020
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,632
-7.16%
|
$134,232
$51.15 P/Share
|
|
Oct 01
2020
|
Michael Douglas Taylor Director |
SELL
Open market or private sale
|
Direct |
125,000
-90.45%
|
$6,375,000
$51.75 P/Share
|
|
Oct 01
2020
|
Michael Douglas Taylor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
125,000
+32.0%
|
$125,000
$1.89 P/Share
|